

Newborn Screening Quality Assurance Program

PROFICIENCY TESTING PROGRAM FOR ANTI-HIV-1 IN DRIED BLOOD SPOTS

Quarterly Report

Quarter 1

February 2015

INTRODUCTION

The Anti-HIV-1 proficiency testing (PT) panel for Quarter 1, 2015, consisted of five individual matrix dried blood spot (DBS) specimens representing a variety of serostatuses. HIV antibody screening and confirmatory tests should identify all HIV-positive specimens, regardless of subtype. Method and laboratory performance are evaluated by challenging participants with specimens representing HIV-negative and positive serostatuses.

On January 13, 2015, we sent the Quarter 1 Anti-HIV-1 panel to 17 domestic and 11 international participants. We received data reports from 26 of the 28 participating laboratories by the designated deadline date. This report is the outcome of data reported for Quarter 1, 2015 Anti-HIV-1 PT specimens, and is distributed to all participants and to program colleagues upon request.

Each participant was asked to analyze the specimens for anti-HIV-1 with the assay schemes they routinely use and to report for each

specimen the screening results along with results from any confirmatory assays performed for presumptive positives. A final interpretation for each specimen must be submitted to receive an evaluation.

There were no false negative and no false positive assessments reported.

PARTICIPANTS' RESULTS

Table 1 shows the overall frequency of reported reactive, non-reactive, and indeterminate screening results for specimens 11541- 11545.

In Part 1 of the report, Table 2 shows the number of laboratories using enzyme immunoassay (EIA) screening methods/kits both for the primary and secondary screens.

Table 3 provides the overall statistics for the screening EIA methods where $N > 3$.

In Part 2 of the report, Table 4 shows the number of laboratories using each confirmatory method/kit.

Table 5 shows the Reported Frequency of Bands by Western Blot for each of the PT specimens that tested positive for the Anti-HIV-1 screening analysis.

The Quality Assurance Program will ship next quarter's HIV-1 DBS proficiency testing specimens on April 13, 2015. ❖

CONFERENCES AND MEETINGS

Keynote Symposia: Mechanisms of HIV Persistence: Implications for a Cure. April 26 - May 1, 2015 Boston, MA, USA

8TH IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22, 2015 Vancouver, British Columbia, Canada



Direct inquiries to:
Centers for Disease Control and Prevention (CDC)
4770 Buford Highway, NE, MS/F43
Atlanta, GA 30341-3724

Quarterly publications for colleagues and participants of the Proficiency Testing Program for Anti-HIV-1 in Dried Blood Spots.

Phone: 770-488-7897
FAX: 770-488-4255
E-mail: IWilliams1@cdc.gov

Editor: Joanne V. Mei
Irene S. Williams



Anti-HIV-1 PT Report
Quarter 1, February 2015

TABLE 1: Frequency Distribution: Outcome of Final Interpretations (26 Laboratories)

Specimen Number	Expected Results	Non- Reactive	Reactive	Indeterminate
11541	Non-Reactive	25	0	1
11542	Non-Reactive	24	0	2
11543	Non-Reactive	26	0	0
11544	Non-Reactive	26	0	0
11545	Reactive	0	26	0

Part 1. SCREENING

TABLE 2: Number of EIA Screening Methods Reported; Includes Primary and Secondary Methods

Method Code	Kit Source	Participants
10	Fujirebio Serodia-HIV 1,2	1
11	In House	1
12	Other	2
27	Tecnosuma (Cuba) UMELISA HIV 1+2	3
40	Avioq HIV-1 Microeleisa Systems	12
41	Bio-Rad HIV-1/HIV-2 plus O EIA	1
43	Murex® HIV-1.2.O. Diasorin	<u>2</u>
Total:		22*

*Note: Four laboratories did not report EIA data and reported final interpretations based on a Western Blot confirmatory test.

Anti-HIV-1 PT Report

Quarter 1, February 2015

TABLE 3: Overall statistics from the EIA method screening assay (N_≥3)

METHOD	STATISTIC	SPECIMEN				
		11541	11542	11543	11544	11545
Avioq HIV-1 Microelisa System (N=12)	OUTLIERS	0	0	0	0	0
	MEAN	0.092	0.096	0.102	0.103	2.794
	SD	0.015	0.025	0.025	0.014	0.264
	UL 95%	0.122	0.145	0.150	0.129	3.311
	LL 95%	0.063	0.048	0.053	0.076	2.277
TECHNOSUMA UMELISA HIV 1+2 (N=3)	OUTLIERS	1	1	1	1	1
	MEAN	0.142	0.163	0.166	0.191	1.688
	SD	0.080	0.096	0.061	0.075	0.065
	UL 95%	0.298	0.351	0.285	0.338	1.816
	LL 95%	0.000	0.000	0.047	0.044	1.560

PART 2. CONFIRMATORY

TABLE 4: Number of Confirmatory Methods Reported

Method Code	Kit Source	Total Participants
12	DAVIH Blot	1
16	Genetic Systems HIV-1 WB Kit (Bio-Rad)	13
32	Cambridge Biotech HIV-1 WB Kit (Maxim)	2
36	New LAV Blot I (Bio-Rad)	1
37	Genelab Diagnostics HIV 2.2 WB	1
42	MP Diagnostics HIV Blot 2.2	1
Total:		19

TABLE 5: Reported Frequency of Bands for Reactive Specimens (All Methods)

Total # Labs (19)	gp160	gp120	p66	p55	p51	gp41	p31	p24	p18
Number of Laboratories Finding Reactive Bands									
Specimen 11545 (R)	19	18	17	13	16	18	17	18	8

This **NEWBORN SCREENING QUALITY ASSURANCE PROGRAM** report is an internal publication distributed to program participants and selected program colleagues. The laboratory quality assurance program is a project cosponsored by the **Centers for Disease Control and Prevention (CDC)** and the **Association of Public Health Laboratories**.

CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)
ATLANTA, GA 30341

Director

Thomas R. Frieden, M.D., M.P.H.

Director

National Center for Environmental Health

Patrick Breyse, Ph.D.

Director

Division of Laboratory Sciences

James L. Pirkle, M.D., Ph.D.

Chief

Newborn Screening and Molecular Biology Branch

Carla Cuthbert, Ph.D.



Contributors: Barbara W. Adam
Paul Dantonio
Victor R. De Jesus, Ph.D.
Marie C. Earley, Ph.D.
Sharon Flores
David Foreman
Stephanie Foster
Elizabeth M. Hall
Christopher Haynes, Ph.D.
Sarah Klass
Francis Lee, Ph.D.
Lixia Li, Ph.D.
Timothy Lim, Ph.D.
Daniel Mandel, Ph.D.
Joanne Mei, Ph.D.
Patrick Pickens
Kelsey Sheard
Jennifer Taylor, Ph.D.
Robert Vogt, Ph.D.
Irene Williams
Golriz Yazdanpanah
Hui Zhou, Ph.D.
Sherri Zobel

Production: Sarah Brown
Iris Landers
Felicia Manning
LoNeka Shockley

ASSOCIATION OF PUBLIC HEALTH LABORATORIES
SILVER SPRING, MD 20910

President

Dan Rice, DrPH, MS.

Chairman, Newborn Screening and Genetics in Public Health Committee

Susan M. Tanksley, Ph.D.

Chairman, Newborn Screening Quality Assurance Quality Control Subcommittee

Patrick Hopkins, B.S.



INQUIRIES TO:

Irene Williams, Editor • Centers for Disease Control and Prevention (CDC)
Newborn Screening Quality Assurance Program • Mailstop F-43
4770 Buford Highway, N.E. • Atlanta, GA 30341-3724
Phone (770) 488-4582 • FAX (770) 488-4255 • E-mail: IWilliams1@cdc.gov